ADXBLADDER: A Novel Non-Invasive Aid for Bladder Cancer Monitoring

The innovative Arquer Diagnostic urine test for bladder cancer adds recurrence monitoring to the approved indications

Sunderland, January 22nd 2019. After succesfully launching ADXBLADDER urine test for the detection of bladder cancer, Arquer Diagnostics announces today the addition of bladder cancer recurrence monitoring as a new indication for use.
“The clinical data supporting this new indication are very consistent with the results observed in all our clinical studies” observes Nadia Whittley, CEO of Arquer Diagnostics. “The reproducibility of the results on a large patient population is a strong indicator of the effectiveness of this diagnostic test. We are now completing the 2000 patients multicentric European study, and the high sensitivity, especially in high grade tumors, coupled with unprecedented negative predicted value continue to be observed, giving our clinical study investigators high confidence in the performance of the test.”

ADXBLADDER measures levels of the MCM5 protein, which is a marker of cells that are replicating, or still have the capability to replicate (i.e. are not terminally differentiated). Such cells are normally only found in basal layers of the epithelium, but when a mass of replicating cells is present (as occurs in bladder cancer), MCM5 cells are shed into bodily fluids. MCM5 in the urine is indicative of undifferentiated cells in an inappropriate location. Detection utilizes standard Enzyme Linked ImmunoSorbent Assay (ELISA) methodology, using mouse monoclonal antibodies to identify MCM5 antigens.

ADXBLADDER is clearly performing consistently across a large population and is demonstrating very exciting results in the detection of recurrent disease- particularly high grade tumours that are at high risk of progression.” said Prof Palou , PI of the ongoing European Study from Fundacio Puigvert Barcelona.

ADXBLADDER is available in all European countries; for more information consult the Arquer Diagnostics web site.

For further information:

Corporate & Clinical Enquiries:

Arquer Diagnostics +44 (0) 191 516 6765
info@arquerdx.com
www.arquerdx.com

About Arquer Diagnostics Ltd

ADXBLADDER, a non-invasive bladder cancer diagnostic test, is the first product to be launched by Arquer Diagnostics. Arquer Diagnostics, launched in 2015, is a company based on the development of non-invasive cancer diagnostic tests using the MCM5 (minichromosome maintenance protein) platform. The mission of Arquer Diagnostics is to deliver accurate, rapid, minimally invasive oncology diagnostic products. Arquer Diagnostics, who are headquartered in Sunderland, United Kingdom, are supported by an international medical advisory board. ADXBLADDER is currently commercialized in Europe and will be further released to other regions in 2019.

Arquer CEO Nadia Whittley Named Among Top 50 Female ‘Movers & Shakers’ in BioBusiness Report

Arquer Diagnostics Ltd (“Arquer”), a UK-based company focusing on the development of non-invasive cancer diagnostic tests today announced that CEO Nadia Whittley has been named among the top 50 ‘Movers & Shakers’ in BioBusiness 2018 report, compiled by BioBeat, an organization dedicated to connecting entrepreneurs with the leaders in biotech.

Now in its fifth year, The BioBeat Movers & Shakers report identifies women who are developing revolutionary bioscience products for healthcare, shaping entrepreneurial bioscience through investment, accelerating the innovation pipeline, transforming patient access to healthcare and supporting innovation from concept to market. Arquer CEO Nadia Whittley’s efforts have been recognized within the contributions to Science section of the report, joining a host of other female influencers who are making significant contributions to the UK biomedical community and economy.

The recent launch and commercialisation of the ADXBLADDER cancer diagnostic test and the restructuring of the Arquer Diagnostics business to streamline clinical, market access and commercial strategies were key achievements reflected in Nadia’s listing within this power list.

To read the full BioBeat 2018 Movers and Shakers report, please click this link here BioBeat 18 50 MS 151018 14.00

– ENDS –

About Arquer Diagnostics

Arquer Diagnostics (www.arquerdx.com) headquartered in Sunderland, United Kingdom, is a company focused on the development of non-invasive cancer diagnostic tests, based on the MCM5 (minichromosome maintenance protein) platform.  Arquer Ltd was launched in 2015, following a strategic decision to put into action the powerful research that had been conducted by a small enterprise, founded in 2005 by Nick Miller-Jones (UroSens). Since then, the company has amassed strong clinical data to support the launch of its first product ADXBLADDER, a bladder cancer diagnostic test, and is running a number of clinical trials to validate many other indications. Arquer is supported by first class international Medical Advisory Boards and together we are aiming at inspiring transformational change in the field of oncology diagnostics.

Contact: Arquer Diagnostics Ltd

T: +44 (0) 191 516 6765

E: info@arquerdx.com

www.arquerdx.com

Arquer Diagnostics Nominated For Two Upcoming Awards

With Spring approaching, Arquer Diagnostics are delighted to announce that we have been nominated for yet another healthcare business award. Hot on the heels of our nomination within the Innovation category at the 2018 North East Business Awards, our team has now been shortlisted in the Medilink Northern Powerhouse Healthcare Business Awards.

Once again, Arquer have been recognised within the Innovation category for our continued research and development into new, non-invasive alternatives to traditional cancer diagnostic methods – including our groundbreaking urine-based bladder cancer test, ADXBLADDER. It is an honour to have our hard work and dedicated to excellence acknowledged by such a prestigious event.

Medilink Northern Powerhouse Healthcare Business Awards

Medilink 20 recognises achievements by healthcare organisations throughout the Northern Powerhouse region, spanning the North West, North East, Yorkshire and the Humber. Achievements in innovation, digital health, primary care, acute care and exports will all be celebrated on March 7th at the Lowry Hall in Manchester. To be nominated amongst such pioneering organisations makes for a stiff competition, but Arquer’s own Tristan Sillars hopes to accept the Innovation award for our team on this special evening.

North East Business Awards

As we wait to hear whether this latest award will be going home with the Arquer team, Louise Flintoft and Arquer CEO, Nadia Whittley will be preparing to appear at the North East Business Awards the following night! Falling just one night after Medilink 20, this event comes to Ramside Hall in Durham on March 8th to toast to a whole host of groundbreaking businesses throughout Durham, Sunderland and South Tyneside, including Arquer Diagnostics.

We hope to be able to take home one, or even both of these amazing awards. This is proving to be a very exciting time for the Arquer Diagnostics team, with so many more developments to look forward to in the near future. Keep your eye on our social media channels and our website for updates on our progress and the results from both award ceremonies next month! Click here to contact us for more information.

The Signs & Symptoms Of Prostate Cancer

ADXPROSTATE

As you may already know, the most common cancer among men in the European Union is prostate cancer, with upwards of 40,000 new cases diagnosed every year. It is one of the biggest health concerns facing men today, and yet accuracy in the current diagnostic tests is poor.

This is not helped by the fact that prostate cancer tends to develop rather slowly, often presenting no symptoms in the early stages. Arquer Diagnostics believe unequivocally that more can be done to improve diagnostic standards. Tests like the PSA blood test result in too many unnecessary biopsies, which has cost implications for the NHS and causes much discomfort and distress for the patient.

Arquer are excited to be approaching the point where a clinical trial is imminent for the new non-invasive ADXPROSTATE diagnostic test, but until this product is ready, it is important to know what signs and symptoms look out for when it comes to prostate cancer.

Early Symptoms

Some of the earliest symptoms arise once the cancer starts putting pressure on the urethra due to its size. As a result, complications may start to occur involving urination, including both difficulties when passing urine, as well as the need to urinate more frequently.

Frequent urination often affects the patient during the night, although the flow may be weak or interrupted or may burn and it’s not uncommon to feel as though your bladder has not fully emptied afterwards. Other symptoms to look out for include blood in your semen or urine, painful ejaculation, difficulty in having an erection and pressure or pain in the rectum and pain or stiffness in the lower back, hips, pelvis, or thighs.

Don’t be alarmed if you notice that your prostate appears to have grown as you’ve aged. This is a common, non-cancerous occurrence professionally known as benign prostatic hyperplasia, or simply “prostate enlargement.”

When To Consult With Your GP

If you are at all concerned, or believe you have experienced any of the above symptoms, it is important to consult with your GP so as to get to the bottom of the problem, even if you’re symptoms are only mild.

Early and accurate diagnosis is the key to prostate cancer survival, which is why Arquer Diagnostics has initiated clinical trials to demonstrate the diagnostic accuracy in prostate cancer of its new product, ADXPROSTATE. ADXPROSTATE is based on the same technology as the recently launched ADXBLADDER. Keep your eyes out for more news updates in the coming months as Arquer Diagnostics continue to fulfill their mission to inspire transformational change in the field of diagnostic oncology.

Contact us here for any further infomation.

ARQUER DIAGNOSTICS WINS AT BRIGHT IDEAS IN HEALTH AWARDS

Arquer Diagnostics are proud to announce that ADXBLADDER was chosen as the winner of the Outstanding Industry Collaboration with the NHS at the 2017 Bright Ideas in Health Awards, which took place on November 17th in Newcastle.

BIHA 2017

Now in their 14th year, these prestigious awards are dedicated to celebrating both individuals and teams and their subsequent achievements, whether they work within the NHS, industry and academia. Through improved service delivery or technical innovation, they will have shown how and where improvements to patient service can be improved.

Arquer Diagnostics, in partnership with teams at City Hospitals Sunderland NHS Foundation Trust, South Tees Hospitals NHS Foundation Trust and Cumbria NHS Trust, submitted their entry for ADXBLADDER – a breakthrough, non-invasive urine test for bladder cancer – for the Outstanding Industry Collaboration with the NHS award. This category recognises industry and NHS collaborations which address a significant need and will have a major impact and benefit for patient care versus previous treatments – including reduction in treatment time, cost savings etc.

Arquer proudly shared their category with two other inspiring finalists this year, however ADXBLADDER triumphed overall, highlighting the importance of fast and accurate bladder cancer testing as a worldwide need.

Arquer DX & ADXBLADDER

“This industry collaboration award recognises Arquer’s vision and its commitment to deliver transformational change in oncology diagnostics,” says Nadia Whittley, CEO of Arquer Diagnostics. “By working with leading NHS clinical teams in the North East and throughout the UK, we are proud to have developed a unique and innovative solution with ADXBLADDER, delivering simple, accurate and non-invasive testing for bladder cancer. This is only the beginning: more NHS Trusts have been engaged to work on new cancer diagnostic tests which we hope will have a major positive impact on the lives of cancer patients worldwide”.

Present at the awards ceremony were representatives of the Arquer Diagnostics team – Nadia Whittley, Tristan Sillars and Louise Flintoft, alongside representatives of the partnership NHS institutions – Mr Stuart McCraken, Consultant Urologist at City Hospitals Sunderland NHS Foundation Trust, Sue Asterling, Urology research nurse, and Jo Cresswell, Consultant Urologist at James Cook University Hospital.

The Arquer DX team is extremely proud and honoured to accept such a prestigious award that demonstrates the impact that ADXBLADDER is already having and will continue to have within urology. This kind of recognition only fuels the passion behind the product, making the hard work and dedication all the more worthwhile. A non-invasive diagnostics test such as this is truly groundbreaking, eliminating the need for uncomfortable, invasive tests and significantly improving the patient experience. With ADXBLADDER, bladder cancer can be accurately diagnosed earlier to allow for a better chance of survival, and the Arquer team are already working to apply this ingenious technology to additional clinical indications.

For more information regarding ADXBLADDER and Arquer Diagnostics, visit their website or follow them on the following social media channels such as InstagramTwitter, LinkedIn & Facebook.

US Bladder Health Month

Many of us tend not to think about our bladder health, or how much this vital organ can affect our lives – which is why campaigns like US Bladder Health Month are incredibly important.

Bladder health ranges from incontinence, urinary tract infections (UTIs) and other smaller issues to serious conditions like bladder cancer, yet many of us believe that minor conditions aren’t ‘important’ and potentially delay seeking medical attention. By taking a more active role in our bladder health and sharing these issues, we can initiate a movement of positive change that could benefit the lives of millions worldwide.

The Statistics

Statistically, 33 million Americans suffer with an overactive bladder, while 50% of American women over the age of 65 battle stress urinary incontinence (SUI) on a daily basis. These numbers are staggering and are reflective of a worldwide trend. Too many people suffer in silence, lacking the confidence to seek the professional help of a GP for fear of embarrassment. However, there are steps that can be taken to improve these conditions if more people find the courage to bring them to the attention of a physician.

When it comes to bladder cancer, the statistics are even more alarming. This cancer has the highest recurrence rate and the highest cost of health care delivery per patient than any other malignancy. Every year in the US, bladder cancer claims 16,000 lives. This is why early and accurate diagnosis is vital for successful treatment and survival, especially as bladder cancer can often be mistaken for non-cancerous gynaecological problems in women.

Testing, Testing

In women it is not uncommon for symptoms of bladder cancer to be confused with UTIs, meaning they may not feel it is necessary to visit the GP. In addition, physicians may be falsely reassured when they diagnose a positive UTI infection when actually there can be more than one process going on.

Standard testing procedure for suspected bladder cancer usually involves a cystoscopy – where a narrow tube with a camera on the end (known as the cystoscope) is inserted through the duct carrying urine out of the bladder (urethra) to allow pictures to be taken of the inside of the bladder. This test can be uncomfortable and invasive for the patient, and due to the high recurrence rate of bladder cancer, patients may need to be retested several times per year.

Arquer Diagnostics is currently in talks with the US FDA and medical key opinion leaders in the hopes that our ground-breaking non-invasive bladder cancer diagnostic test, ADXBLADDER, can soon be introduced efficiently and safely throughout the country.

ADXBLADDER

ADXBLADDER is a new non-invasive test for bladder cancer that was launched in the UK, France, Italy and Turkey in October 2017. The test, which requires just 10ml of urine, uses ELISA antibody technology available in most hospital laboratories to measure levels of a protein called MCM5 that is found in dividing cells, and is only present in the urine if a tumour is present. Key features of the test include results being available within three hours, providing a clear cut yes/ no answer of whether the patient has cancer.

For further information regarding ADXBLADDER, refer to the Arquer Diagnostics website or get in touch via our contact details. Please also feel free to browse our recent press features. It’s time to end the silence and speak out this November for Bladder Health Month.

Arquer Diagnostics Wins Outstanding Industry Collaboration at Bright Ideas in Health Awards

Newcastle, 17th November 2017: Arquer Diagnostics are proud to announce their status as Winners of the Outstanding Industry Collaboration with the NHS category at the 2017 Bright Ideas in Health Awards, which took place in Newcastle this week.

These prestigious awards celebrate the achievements of individuals and teams working within the NHS, industry and academia, who have risen to the challenge of showing how and where improvements to patient service can be improved, either through technical innovation or better service delivery.

Arquer Diagnostics in partnership with the teams at Sunderland Royal Hospital, South Tees Hospitals NHS Foundation Trust and Cumbria NHS Trust submitted their entry for ADXBLADDER – a breakthrough, non-invasive urine test for bladder cancer – for the Outstanding Industry Collaboration with the NHS award. This category recognises industry and NHS collaborations which address a significant need and will have a major impact and benefit for patient care versus previous treatments – including reduction in treatment time, cost savings etc.

“This industry collaboration award recognises Arquer’s vision and its commitment to deliver transformational change in oncology diagnostics,” says Nadia Whittley, CEO of Arquer Diagnostics. “By working with leading NHS clinical teams in the North East and throughout the UK, we are proud to have developed a unique and innovative solution with ADXBLADDER, delivering simple, accurate and non-invasive testing for bladder cancer. This is only the beginning: more NHS Trusts have been engaged to work on new cancer diagnostic tests which we hope will have a major positive impact on the lives of cancer patients worldwide”. 

Present at the awards ceremony were representatives of the Arquer Diagnostics team – Nadia Whittley, Tristan Sillars and Louise Flintoft, alongside representatives of the partnership NHS institutions – Mr Stuart McCraken, Consultant Urologist at Sunderland Hospital, Sue Asterling, Urology research nurse, and Jo Cresswell, Consultant Urologist at James Cook University Hospital.

Movember – Raising Money For Men’s Health

For almost 14 years, the Movember Foundation has been dedicated to raising money and spreading awareness of some of the biggest health issues currently facing men, including both prostate and testicular cancer, mental health and suicide prevention.

The ultimate goal is to eliminate premature death in men, with the hope that the number of men dying too soon will drop 25% by 2030. Each November, men across the world come together to raise money for men’s health causes by growing out their moustache for the month in return for sponsorship. However, there are so many fun ways to get involved for men and women alike – below are some of our suggestions, and you can find more information on the Movember website.

Men’s health is a cause close to our hearts here at Arquer Diagnostics and we’d love to hear how you’re getting involved this Movember, so don’t hesitate to get in touch and tag us on social media so that we can engage and share your efforts.

Grow Your Mo’!

It’s a classic for the fellas. Get into the true spirit of Movember and get sponsored to grow your moustache for 30 days. This can be a real challenge if you’re not used to having facial hair, but you never know, you might even come to like it!

movember

Move For Movember

This is one that we can all do! Whether you walk, run, swim or cycle, challenge yourself to go the distance this November for a great cause. It’s all about having fun and raising money, so if you want to beat your personal best or get together with friends for a group activity, every little helps. Not to mention the added benefit to your own health that comes with exercise.

Healthy Competition

Whatever you’re doing for Movember, whether you’re growing your tash or getting active, there’s always a way to make it even more fun by turning it into a competition.

Who can grow the longest moustache at your office? Who can raise the most money out of your friends? Split into teams to make it even more exciting – perhaps a Movember boys vs. girls quiz to determine once and for all who is smarter. Which team can outrun the other? The possibilities are endless.

Arquer DX Prostate Cancer Test

Following the recent success with ADXBLADDER, Arquer Diagnostics are launching a revolutionary, non-invasive diagnostic test for prostate cancer in 2018. Keep your eyes peeled for more information on this and our clinical trials.